ADC Therapeutics (ADCT) Deferred Taxes (2023)

ADC Therapeutics (ADCT) posted Deferred Taxes of $42.9 million for Q4 2023, up 7514.19% sequentially from -$578000.0 in Q3 2023.

ADC Therapeutics (ADCT) Deferred Taxes (2023) Analysis & Trends

ADC Therapeutics has reported Deferred Taxes for 1 years, with the latest figure at $42.9 million in Q4 2023.

Quarterly Deferred Taxes changed N/A year-over-year to $42.9 million in Q4 2023, while the trailing twelve-month figure through Sep 2024 was $42.9 million (changed N/A YoY) and the FY2023 annual result came in at $37.1 million, up 2388.96% from the prior year.
Deferred Taxes grew to $42.9 million in Q4 2023 per ADCT's latest filing, from -$578000.0 in the prior quarter.
Over five years, Deferred Taxes peaked at $42.9 million in Q4 2023 and troughed at -$5.1 million in Q2 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Deferred Taxes (Qtr)
1	Vertex Pharmaceuticals	140.22 Bn	132.37 Bn	2.84 Bn	-69.70 Mn
2	Regeneron Pharmaceuticals	86.29 Bn	78.30 Bn	3.93 Bn	194.40 Mn
3	Argenx Se	65.17 Bn	59.98 Bn	1.37 Bn	-
4	Moderna	61.38 Bn	56.24 Bn	52.00 Mn	-
5	BeOne Medicines	42.18 Bn	37.09 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	30.99 Bn	27.68 Bn	992.69 Mn	2.66 Mn
7	BioNTech SE	28.45 Bn	10.05 Bn	668.28 Mn	-
8	Insmed	27.47 Bn	26.31 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	ADC Therapeutics	152.38 Mn	-66.73 Mn	17.14 Mn	-

Download Data